SE8702463L - Ligander och forfaranden for att oka b-cell-proliferation - Google Patents

Ligander och forfaranden for att oka b-cell-proliferation

Info

Publication number
SE8702463L
SE8702463L SE8702463A SE8702463A SE8702463L SE 8702463 L SE8702463 L SE 8702463L SE 8702463 A SE8702463 A SE 8702463A SE 8702463 A SE8702463 A SE 8702463A SE 8702463 L SE8702463 L SE 8702463L
Authority
SE
Sweden
Prior art keywords
cell proliferation
ligands
oka
procedures
proliferation
Prior art date
Application number
SE8702463A
Other languages
Unknown language ( )
English (en)
Other versions
SE8702463D0 (sv
SE504675C2 (sv
Inventor
J Ledbetter
E A Clark
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of SE8702463D0 publication Critical patent/SE8702463D0/sv
Publication of SE8702463L publication Critical patent/SE8702463L/sv
Publication of SE504675C2 publication Critical patent/SE504675C2/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE8702463A 1986-06-13 1987-06-12 Ligander för att öka B-Cell-Proliferation SE504675C2 (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87388486A 1986-06-13 1986-06-13

Publications (3)

Publication Number Publication Date
SE8702463D0 SE8702463D0 (sv) 1987-06-12
SE8702463L true SE8702463L (sv) 1987-12-14
SE504675C2 SE504675C2 (sv) 1997-04-07

Family

ID=25362524

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8702463A SE504675C2 (sv) 1986-06-13 1987-06-12 Ligander för att öka B-Cell-Proliferation

Country Status (22)

Country Link
JP (1) JPH0762040B2 (sv)
KR (1) KR910004100B1 (sv)
AT (1) AT398437B (sv)
AU (1) AU617087B2 (sv)
BE (1) BE1000587A4 (sv)
CA (1) CA1338781C (sv)
CH (1) CH676600A5 (sv)
CY (1) CY1681A (sv)
DE (1) DE3719398C2 (sv)
DK (1) DK173940B1 (sv)
FR (1) FR2607136B1 (sv)
GB (1) GB2191494B (sv)
GR (1) GR870930B (sv)
HK (1) HK10293A (sv)
IE (1) IE60486B1 (sv)
IL (1) IL82841A (sv)
IT (1) IT1208649B (sv)
LU (1) LU86919A1 (sv)
NL (1) NL195022C (sv)
PT (1) PT85073B (sv)
SE (1) SE504675C2 (sv)
SG (1) SG118992G (sv)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
EP0117705A3 (en) * 1983-02-24 1985-09-25 The Regents Of The University Of California Monoclonal antibody specific for monocytes and blast cells
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
US4585742A (en) * 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof

Also Published As

Publication number Publication date
IL82841A0 (en) 1987-12-20
SE8702463D0 (sv) 1987-06-12
AU617087B2 (en) 1991-11-21
GB8713650D0 (en) 1987-07-15
NL8701371A (nl) 1988-01-04
SG118992G (en) 1993-01-29
GR870930B (en) 1987-12-16
IE871563L (en) 1987-12-13
IE60486B1 (en) 1994-07-27
IL82841A (en) 1992-11-15
GB2191494A (en) 1987-12-16
CH676600A5 (sv) 1991-02-15
DE3719398A1 (de) 1988-01-28
PT85073B (pt) 1990-07-31
GB2191494B (en) 1990-08-22
FR2607136A1 (fr) 1988-05-27
KR910004100B1 (ko) 1991-06-22
JPS6480299A (en) 1989-03-27
SE504675C2 (sv) 1997-04-07
DK173940B1 (da) 2002-03-04
ATA151387A (de) 1994-04-15
HK10293A (en) 1993-02-19
JPH0762040B2 (ja) 1995-07-05
DK302287A (da) 1987-12-14
NL195022C (nl) 2003-06-18
CY1681A (en) 1993-10-10
DK302287D0 (da) 1987-06-12
AT398437B (de) 1994-12-27
PT85073A (en) 1987-07-01
AU7421487A (en) 1987-12-17
IT1208649B (it) 1989-07-10
IT8720899A0 (it) 1987-06-12
BE1000587A4 (fr) 1989-02-14
LU86919A1 (fr) 1989-03-08
KR880000582A (ko) 1988-03-28
FR2607136B1 (fr) 1989-09-15
DE3719398C2 (de) 1996-03-28
CA1338781C (en) 1996-12-10

Similar Documents

Publication Publication Date Title
SE8104494L (sv) Alkylerade eller arylerade kiselkarbidforpolymerer
IT1142747B (it) Perfezionamento nelle lime dentali endontiche
JPS5291023A (en) Manufacture of portland cement and use of waste material
GB2109684B (en) Serum thymic factor for use in the treatment of immuno deficiency
FR2519997B1 (fr) Melange adhesif polyethylenique et structure composite comprenant ledit melange
AU3614384A (en) Anti-idiotype antibodies & their use in inducing immulogical response to viruses & tumours
SE8104497L (sv) Kiselkarbidforpolymerer
DE3587257D1 (de) Ylide-pyridinium-polymeren und daraus hergestellte materialien.
DE58909630D1 (de) Photopolymerisierbares Gemisch und dieses enthaltendes photopolymerisierbares Aufzeichnungsmaterial
BR8406962A (pt) Material composito cimenticeo
TR28355A (tr) Hidrolik cimento "BUGHOLE" (bosluk) sayisini azaltici ilave karisimlar ve bunlarin kullanimi ile ilgili yöntem.
IT7923761A0 (it) Procedimento e dispositivo per la fabbricazione di lastre di cemento rinforzante.
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
MX154850A (es) Mejoras en aparato para calcinar yeso y materiales similares
IT1188236B (it) Perfezionamenti apportati al trattamento di materiali in particelle
SE8702463L (sv) Ligander och forfaranden for att oka b-cell-proliferation
IT1164200B (it) Procedimento di fabbricazione di carburo di calcio da calce/pietra da calce in polvere
ES516598A0 (es) "procedimiento de preparacion de materiales compuestos ceramizados".
GB2018258A (en) 3 acetoxy & 11 epoxy pregna 3,5 dienes and 1,3,5 trienes and their use in the synthesis of 6 halocorticoids
AT337591B (de) Vorrichtung zur warmebehandlung von pulverformigen materialien, insbesondere von zementrohstoff
BE884728A (fr) Slip pour homme
IT1024627B (it) Procedimento e dispositivo per la testurizzazione di materiali proteici particellari
DE58905961D1 (de) Ultrazentrifuge zur Bestimmung von Teilchengrössenverteilungen.
DE3481534D1 (de) Verteilung und dosieren von kraftstoff.
BE871291A (fr) Plaque d'un seul tenant en matiere elastique, notamment pour l'absorption des vibrations

Legal Events

Date Code Title Description
NUG Patent has lapsed